estrogen receptor

Dec 29, 2021

Regor Therapeutics to Begin US CDK2/4/6 Inhibitor Study for HR-Positive, HER2-Negative Breast Cancer

Dec 7, 2021

ESR1 Mutation Testing May be Informative for Personalizing SERD Treatment, SABCS Studies Show
Premium

Nov 15, 2021

Drugmakers Trying Out Decentralized Clinical Trials in Precision Oncology Though Risks Remain
Premium

Oct 14, 2021

Veru Launches Registrational Trial of Anti-Androgen Drug Enobosarm for Metastatic Breast Cancer

May 6, 2021

GE Healthcare Acquiring Zionexa for Access to Breast Cancer PET Imaging Agent

Apr 12, 2021

Keytruda, Hormone Therapy Combination Benefits Advanced Breast Cancer Subgroup in AACR Study

Apr 9, 2021

Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

Oct 1, 2020

Sermonix Expands Lasofoxifene Breast Cancer Study to Canadian Sites

Sep 20, 2020

Conflicting ESMO Data Raise Questions About Role of CDK4/6 Inhibitors in Adjuvant Breast Cancer
Premium

Sep 15, 2020

Bayer Pays Systems Oncology $25M Upfront to License ER-Positive Breast Cancer Drug

Jul 22, 2020

Olema Oncology Raises $54M in Series B Financing Round

Jul 8, 2020

Eli Lilly, Sermonix Pharma Partner on Phase II Trial of Drug Combo in Metastatic Breast Cancer

Apr 22, 2020

AstraZeneca's Capivasertib, Fulvestrant Combo Shows Promise in AKT1 E17K-Mutated Breast Cancer

Jan 10, 2020

OncotypeDX Score May Give Valuable Info on Breast Cancer Locoregional Recurrence

Jun 13, 2019

ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer
Premium